X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isosorbide Dinitrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Frandol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 05, 2021
Details:
In accordance with this agreement TOA EIYO will independently sell and provide information on all 18 products such as Bisono® tape for treatment of hypertension and atrial fibrillation and Frandol® tablets and tape for treatment of ischemic heart disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Urapidil Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ebrantil
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hasten
Deal Size: $322.0 million Upfront Cash: Undisclosed
Deal Type: Divestment December 21, 2020
Details:
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China which includes Ebrantil®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bempedoic Acid,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nustendi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Edoxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Du-176b
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation therapies.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
